For example, trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor-2 (HER-2) is approved by the Food and Drug Administration (FDA) as a first-line treatment of HER-2-positive cancer [65]. Here, ERBB2 is linked to cancer.